US FDA Approves Merck HIV Pill Combo, Expands Treatment Options

Published On Apr 23, 2026 | Source: ET Pharma

US FDA Approves Merck HIV Pill Combo for Adults with HIV-1

The US FDA approves Merck HIV pill combo development marks a significant milestone in HIV treatment, as regulators have cleared a new once-daily oral therapy designed to simplify disease management. The approval introduces an additional treatment option for adults living with HIV-1.

The newly approved therapy, branded as Idvynso, combines doravirine and islatravir into a single-tablet regimen. The drug is intended for patients who are already virologically suppressed and are switching from existing antiretroviral therapies.

Clinical Trial Results and Efficacy

Clinical studies involving more than 1,000 patients demonstrated that the combination therapy effectively suppresses HIV-1 replication. The regimen showed non-inferior efficacy compared to standard treatments, reinforcing its potential as an alternative therapy option.

The US FDA approves Merck HIV pill combo decision is supported by Phase 3 trial data, which confirmed comparable safety and effectiveness to existing three-drug regimens. :contentReference[oaicite:0]{index=0}

How the Drug Works

Doravirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI), while islatravir is a novel nucleoside reverse transcriptase translocation inhibitor. Together, they block the replication of the HIV virus, helping maintain viral suppression in patients.

This two-drug combination represents a shift toward simplified treatment regimens, reducing pill burden while maintaining therapeutic effectiveness.

Regulatory standards for such approvals are guided by the U.S. Food and Drug Administration (FDA).

Market Impact and Industry Outlook

The US FDA approves Merck HIV pill combo announcement strengthens Merck’s position in the competitive HIV treatment market. The new regimen is expected to provide an alternative for patients seeking simpler dosing schedules.

Globally, HIV remains a major health challenge. According to global estimates, over 40 million people are living with HIV, highlighting the ongoing need for innovative therapies. :contentReference[oaicite:1]{index=1}

Future Outlook

Looking ahead, the US FDA approves Merck HIV pill combo development may pave the way for further innovation in HIV treatment, including long-acting and simplified regimens.

While the initial commercial impact may be gradual, experts believe the therapy could play a key role in expanding treatment options and improving patient adherence over time.